Powerful 4-Drug cocktail aims to crush myeloma early
NCT ID NCT03500445
First seen Nov 01, 2025 · Last updated May 14, 2026 · Updated 25 times
Summary
This study tests a combination of four drugs (daratumumab, carfilzomib, lenalidomide, and dexamethasone) in 75 people newly diagnosed with multiple myeloma. The goal is to see how many achieve a very deep remission (stringent complete response) and have no detectable cancer cells after 8 cycles of treatment. This approach aims to control the disease aggressively from the start, but ongoing management is still needed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The University of Chicago
Chicago, Illinois, 60637, United States
Conditions
Explore the condition pages connected to this study.